(MIRM) Mirum Pharmaceuticals - Ratings and Ratios

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare and orphan diseases. Its lead product, LIVMARLI (maralixibat), is an orally administered IBAT inhibitor approved for treating cholestatic pruritus in Alagille syndrome patients globally. The company also markets Cholbam, a cholic acid capsule for bile acid synthesis disorders and peroxisomal disorders, and Chenodal, a tablet for gallbladder stones and under Phase 3 development for cerebrotendinous xanthomatosis. Additionally, Mirum is advancing Volixibat, an oral IBAT inhibitor in Phase 2b trials for adult cholestatic liver diseases. Incorporated in 2018, the company is based in Foster City, California.

Based on the technical and fundamental data, here is the 3-month forecast for MIRM:

Technically, MIRM is trading above its 20-day SMA (40.64) and 50-day SMA (44.26), but below its 200-day SMA (42.92), indicating potential short-term strength but longer-term resistance. The ATR of 2.07 suggests moderate volatility. The stock may face resistance near 45 and support around 40.

Fundamentally, MIRM has a market cap of 1.93B USD with a forward P/E of 39.68, indicating high expectations for future earnings. The P/B ratio of 8.57 reflects strong investor confidence in its pipeline. However, the negative RoE (-38.97) raises concerns about profitability. The companys P/S ratio of 5.74 suggests premium valuation relative to sales.

Forecast: MIRM is likely to trade in the range of 40-45 over the next 3 months. Upside may be limited by the 200-day SMA and high forward P/E, while downside could be cushioned by its pipeline progress and rare disease focus.